Shilpa Medicare gets Germany marketing authorization for Amifampridine Tablets
Hyderabad: Shilpa Medicare Limited has received Marketing Authorization from Germany, EU for Amifampridine Tablets, 10 mg under the National Procedure.
Amifampridine is used as a drug, predominantly in the treatment of a number of rare muscle diseases. Specifically, Amifampridine is used to treat Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune disease.
This product has sales of about 20 M USD in Europe. As on date, there is one other approved generic in the market.
Shilpa Medicare Limited started its operations as an API manufacturer way back in 1987 at Raichur, Karnataka- India. The commercial production in the SML was started in November 1989. Today Shilpa Medicare Limited is a global brand in manufacturing and supplying of API and Formulation globally in different regulated markets.
Read also: Shilpa Medicare Jadcherla facility clears TGA, Australia GMP inspection
